RU2013105211A - APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS - Google Patents

APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS Download PDF

Info

Publication number
RU2013105211A
RU2013105211A RU2013105211/15A RU2013105211A RU2013105211A RU 2013105211 A RU2013105211 A RU 2013105211A RU 2013105211/15 A RU2013105211/15 A RU 2013105211/15A RU 2013105211 A RU2013105211 A RU 2013105211A RU 2013105211 A RU2013105211 A RU 2013105211A
Authority
RU
Russia
Prior art keywords
pro
peptide
prevention
gly
treatment
Prior art date
Application number
RU2013105211/15A
Other languages
Russian (ru)
Other versions
RU2538801C2 (en
Inventor
Людмила Александровна Андреева
Татьяна Алимовна Зубова
Марина Евгеньевна Григорьева
Людмила Анисимовна Ляпина
Николай Федорович Мясоедов
Тамара Юрьевна Оберган
Original Assignee
Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" filed Critical Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген"
Priority to RU2013105211/15A priority Critical patent/RU2538801C2/en
Publication of RU2013105211A publication Critical patent/RU2013105211A/en
Application granted granted Critical
Publication of RU2538801C2 publication Critical patent/RU2538801C2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Применение тетрапептида Arg-Pro-Gly-Pro в качестве средства профилактики и лечения гиперхолестеринемии.2. Способ профилактики и лечения гиперхолестеринемии, включающий интраназальное введение лекарственного средства на основе тетрапептида Arg-Pro-Gly-Pro в эффективном количестве.3. Фармацевтическая композиция для профилактики и лечения гиперхолестеринемии, включающая пептид с гипохолестеринемическим действием в качестве активного вещества и фармацевтически приемлемое вспомогательное вещество в качестве консерванта, отличающаяся тем, что в качестве пептида использован пептид общей формулы Arg-Pro-Gly-Pro или его фармацевтически приемлемая соль.4. Композиция по п.3, отличающаяся тем, что содержание пептида или его фармацевтически приемлемой соли составляет 0,1÷1,0 вес.%.5. Композиция по п. 3 или 4, отличающаяся тем, что она выполнена приемлемой для интраназального введения.6. Композиция по п.5, отличающаяся тем, что она выполнена в виде раствора следующего состава: пептид Arg-Pro-Gly-Pro или его фармацевтически приемлемая соль - 1÷10 г/л; нипагин - 0,9÷1,1 г/л в качестве консерванта, дистиллированная вода - до 1 л.7. Способ получения фармацевтической композиции для профилактики и лечения гиперхолестеринемии, включающий смешивание активного и вспомогательных веществ, отличающийся тем, что в качестве активного вещества используют пептид общей формулы Arg-Pro-Gly-Pro или его фармацевтически приемлемую соль.8. Способ по п.7, отличающийся тем, что содержание пептида или его фармацевтически приемлемой соли составляет 0,1÷1,0 вес.%.9. Способ по п.7 или 8, отличающийся тем, что композицию получают в форме, приемлемой для интраназального введения.10. Способ по п.9, о1. The use of the tetrapeptide Arg-Pro-Gly-Pro as a means of prevention and treatment of hypercholesterolemia. 2. A method for the prevention and treatment of hypercholesterolemia, including the intranasal administration of a drug based on the tetrapeptide Arg-Pro-Gly-Pro in an effective amount. 3. A pharmaceutical composition for the prevention and treatment of hypercholesterolemia, including a peptide with hypocholesterolemic action as an active substance and a pharmaceutically acceptable excipient as a preservative, characterized in that the peptide used is a peptide of the general formula Arg-Pro-Gly-Pro or its pharmaceutically acceptable salt. four. The composition according to claim 3, characterized in that the content of the peptide or its pharmaceutically acceptable salt is 0.1 ÷ 1.0 wt.%. 5. A composition according to claim 3 or 4, characterized in that it is made acceptable for intranasal administration. The composition according to claim 5, characterized in that it is made in the form of a solution of the following composition: Arg-Pro-Gly-Pro peptide or its pharmaceutically acceptable salt - 1 ÷ 10 g / l; nipagin - 0.9 ÷ 1.1 g / l as a preservative, distilled water - up to 1 l. 7. A method of obtaining a pharmaceutical composition for the prevention and treatment of hypercholesterolemia, comprising mixing the active and auxiliary substances, characterized in that the active substance is a peptide of the general formula Arg-Pro-Gly-Pro or a pharmaceutically acceptable salt thereof. The method according to claim 7, characterized in that the content of the peptide or its pharmaceutically acceptable salt is 0.1 ÷ 1.0 wt.%. 9. The method according to claim 7 or 8, characterized in that the composition is obtained in a form acceptable for intranasal administration. The method according to claim 9, about

Claims (10)

1. Применение тетрапептида Arg-Pro-Gly-Pro в качестве средства профилактики и лечения гиперхолестеринемии.1. The use of the tetrapeptide Arg-Pro-Gly-Pro as a means of prevention and treatment of hypercholesterolemia. 2. Способ профилактики и лечения гиперхолестеринемии, включающий интраназальное введение лекарственного средства на основе тетрапептида Arg-Pro-Gly-Pro в эффективном количестве.2. A method for the prevention and treatment of hypercholesterolemia, including the intranasal administration of a drug based on the tetrapeptide Arg-Pro-Gly-Pro in an effective amount. 3. Фармацевтическая композиция для профилактики и лечения гиперхолестеринемии, включающая пептид с гипохолестеринемическим действием в качестве активного вещества и фармацевтически приемлемое вспомогательное вещество в качестве консерванта, отличающаяся тем, что в качестве пептида использован пептид общей формулы Arg-Pro-Gly-Pro или его фармацевтически приемлемая соль.3. A pharmaceutical composition for the prevention and treatment of hypercholesterolemia, including a peptide with hypocholesterolemic action as an active substance and a pharmaceutically acceptable excipient as a preservative, characterized in that the peptide used is a peptide of the general formula Arg-Pro-Gly-Pro or its pharmaceutically acceptable salt. 4. Композиция по п.3, отличающаяся тем, что содержание пептида или его фармацевтически приемлемой соли составляет 0,1÷1,0 вес.%.4. The composition according to claim 3, characterized in that the content of the peptide or its pharmaceutically acceptable salt is 0.1 ÷ 1.0 wt.%. 5. Композиция по п. 3 или 4, отличающаяся тем, что она выполнена приемлемой для интраназального введения.5. The composition according to p. 3 or 4, characterized in that it is made acceptable for intranasal administration. 6. Композиция по п.5, отличающаяся тем, что она выполнена в виде раствора следующего состава: пептид Arg-Pro-Gly-Pro или его фармацевтически приемлемая соль - 1÷10 г/л; нипагин - 0,9÷1,1 г/л в качестве консерванта, дистиллированная вода - до 1 л.6. The composition according to claim 5, characterized in that it is made in the form of a solution of the following composition: Arg-Pro-Gly-Pro peptide or its pharmaceutically acceptable salt - 1 ÷ 10 g / l; nipagin - 0.9 ÷ 1.1 g / l as a preservative, distilled water - up to 1 liter. 7. Способ получения фармацевтической композиции для профилактики и лечения гиперхолестеринемии, включающий смешивание активного и вспомогательных веществ, отличающийся тем, что в качестве активного вещества используют пептид общей формулы Arg-Pro-Gly-Pro или его фармацевтически приемлемую соль.7. A method of obtaining a pharmaceutical composition for the prevention and treatment of hypercholesterolemia, comprising mixing the active and auxiliary substances, characterized in that the peptide of the general formula Arg-Pro-Gly-Pro or a pharmaceutically acceptable salt thereof is used as the active substance. 8. Способ по п.7, отличающийся тем, что содержание пептида или его фармацевтически приемлемой соли составляет 0,1÷1,0 вес.%.8. The method according to claim 7, characterized in that the content of the peptide or its pharmaceutically acceptable salt is 0.1 ÷ 1.0 wt.%. 9. Способ по п.7 или 8, отличающийся тем, что композицию получают в форме, приемлемой для интраназального введения.9. The method according to claim 7 or 8, characterized in that the composition is obtained in a form acceptable for intranasal administration. 10. Способ по п.9, отличающийся тем, что композицию получают в виде раствора следующего состава: пептид Arg-Pro-Gly-Pro или его фармацевтически приемлемая соль - 1÷10 г/л; нипагин - 0,9÷1,1 г/л в качестве консерванта, дистиллированная вода - до 1 л. 10. The method according to claim 9, characterized in that the composition is obtained in the form of a solution of the following composition: Arg-Pro-Gly-Pro peptide or its pharmaceutically acceptable salt - 1 ÷ 10 g / l; nipagin - 0.9 ÷ 1.1 g / l as a preservative, distilled water - up to 1 liter.
RU2013105211/15A 2013-02-07 2013-02-07 USING TETRAPEPTIDE Arg-Pro-Gly-Pro AS AGENT FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, METHOD FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA AND METHOD FOR PREPARING IT RU2538801C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2013105211/15A RU2538801C2 (en) 2013-02-07 2013-02-07 USING TETRAPEPTIDE Arg-Pro-Gly-Pro AS AGENT FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, METHOD FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA AND METHOD FOR PREPARING IT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013105211/15A RU2538801C2 (en) 2013-02-07 2013-02-07 USING TETRAPEPTIDE Arg-Pro-Gly-Pro AS AGENT FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, METHOD FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA AND METHOD FOR PREPARING IT

Publications (2)

Publication Number Publication Date
RU2013105211A true RU2013105211A (en) 2014-08-20
RU2538801C2 RU2538801C2 (en) 2015-01-10

Family

ID=51384075

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013105211/15A RU2538801C2 (en) 2013-02-07 2013-02-07 USING TETRAPEPTIDE Arg-Pro-Gly-Pro AS AGENT FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, METHOD FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA AND METHOD FOR PREPARING IT

Country Status (1)

Country Link
RU (1) RU2538801C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2403909C1 (en) * 2009-10-23 2010-11-20 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Method of treating diabetes in mammals and intranasal pharmaceutical composition for treating diabetes in mammals

Also Published As

Publication number Publication date
RU2538801C2 (en) 2015-01-10

Similar Documents

Publication Publication Date Title
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
MX2021006421A (en) Amino-acid anilides as small molecule modulators of il-17.
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
RU2014149181A (en) PYRAZOLE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
EA201290860A1 (en) TREATMENT OF RHEUMATOID ARTHRITIS BY COMBINATION OF LAKVINIMODA AND METHOREXAT
PH12017500136A1 (en) Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof
RU2017118971A (en) Amino Acid Composition for Restoring Fibroelastin in Dermal Connective Tissues
EA201691490A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BRINZOLAMIDE
EA201590193A1 (en) LAKVINIMODA PREPARATIONS WITHOUT AN AGENT AGENT
EA201790223A1 (en) WATER PREPARATION CONTAINING PARACETAMOL AND IBUPROFEN
RU2016112257A (en) COMPOSITION FOR THE TREATMENT OF HYPERTENSION AND / OR FIBROSIS
EA201390950A1 (en) HOMOGENEOUS PHARMACEUTICAL ORAL DOSAGE FORMS CONTAINING LERKANIDIPIN AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS TOGETHER WITH ORGANIC ACID
EA201991490A1 (en) AROMATIC AMIDES OF CARBOXYLIC ACIDS AS BRAKININ B1 RECEPTOR ANTAGONISTS
RU2013105211A (en) APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS
EA201591418A1 (en) MULTICOMPONENT CRYSTAL PARTICLES FOR INHALATION THERAPY
RU2014130894A (en) PEPTID POSSESSING NEUROPROTECTOR AND NOTROPIC ACTIVITY, AND PHARMACEUTICAL COMPOSITION ON ITS BASIS
EA201592297A1 (en) AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS
EA201400484A1 (en) TRANSDERMAL MEANS FOR THE TREATMENT AND PREVENTION OF DISEASES OF JOINT AND SOFT TISSUES
BR112015015938A2 (en) use of phenylephrine and acetaminophen hydrochloride, drug, method of treatment of upper respiratory tract mucosal congestion in an adult human
RU2012135798A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SKIN ITCH
RU2019102890A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FLURBIPROPHEN
RU2013105212A (en) APPLICATION OF PRO-Gly-Pro-Val TETREPEPTIDE AS A MEANS FOR PREVENTION AND TREATMENT OF LIPID METABOLISM DISORDERS, METHOD OF PREVENTION AND TREATMENT OF LIPID METABOLISM VIOLATIONS, PHARMACEUTICAL COMPOSITION
AR074470A1 (en) AMIDA COMPOUND OF THE CYCLOPROPANOCARBOXYL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES
RU2014148062A (en) INJECTION PHARMACEUTICAL COMPOSITION OF DEXKETOPROFEN AND TRAMADOL
MX362435B (en) Novel pharmaceutical system of biphasic delivery for treating pain and inflammation.